Anderson Christopher M, Nedergaard Maiken
Department of Pharmacology and Therapeutics, University of Manitoba and Division of Neurodegenerative Disorders, St Boniface Hospital Research Center, Winnipeg, Canada R2H 2A6.
Trends Neurosci. 2006 May;29(5):257-62. doi: 10.1016/j.tins.2006.03.003. Epub 2006 Mar 27.
Currently available antibodies to the P2X(7) receptor are unreliable determinants of neuronal P2X(7) immunoreactivity, owing to staining of a "P2X(7)-like" protein that is not eliminated by legitimate P2X(7) gene-knockout approaches. Despite this, compelling electrophysiological and pharmacological data strongly support a role for P2X(7) receptors in neuronal function and injury. A major priority for the field now is to identify the neuronal "P2X(7)-like" protein and develop effective antibodies selective for neuronal P2X(7) immunoreactivity. Until this occurs, we are dependent on rigorous application of multiple pharmacological criteria for attribution of neuronal function to P2X(7) receptors in non-human tissues, including greater activity in response to BzATP than to ATP, sensitivity to blockade by nanomolar concentrations of Brilliant Blue-G, irreversible antagonism by periodate-oxidized ATP, and lack of inhibition by suramin.
目前可用的针对P2X(7)受体的抗体并不能可靠地判定神经元P2X(7)免疫反应性,这是因为一种“类P2X(7)”蛋白会被染色,而这种染色不能通过合理的P2X(7)基因敲除方法消除。尽管如此,令人信服的电生理和药理学数据有力地支持了P2X(7)受体在神经元功能和损伤中的作用。该领域目前的一个主要优先事项是鉴定神经元“类P2X(7)”蛋白,并开发对神经元P2X(7)免疫反应性具有选择性的有效抗体。在此之前,我们依赖于严格应用多种药理学标准,以将神经元功能归因于非人类组织中的P2X(7)受体,这些标准包括对BzATP的反应比对ATP的反应更活跃、对纳摩尔浓度的亮蓝-G阻断敏感、高碘酸盐氧化ATP的不可逆拮抗作用以及苏拉明无抑制作用。